FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
PO:14:195 | Real-world effectiveness of anifrolumab in achieving treatment targets and reducing systemic lupus erythematosus disease burden: 6-month interim analysis of the REVEAL study Chiara Cardelli1|2, Chiara Tani1, Luca Moroni3, Filippo Vesentini4, Francesca Bottazzi5, Micaela Fredi6, Ettore Silvagni7, Matteo Piga8, Flavia Riccio9, Fulvia Ceccarelli10, Ginevra De Marchi11, Edoardo Biancalana12, Gianluca Moroncini13, Rita Mulè14, Mariele Gatto15, Laura Coladonato16, Paola Conigliaro17, Maria Gerosa18, Andrea Picchianti Diamanti19, Benedetta Bianchi20, Federica Maiolini20, Michela Gasparotto20, Serena Guiducci20, Maria Ilenia De Andres20, Alberto Lo Gullo20, Silvia Noviello20, On Behalf Of The Reveal Investigators20, Marta Mosca1. | 1Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa; 2Department of Medical Biotechnologies, University of Siena, Siena; 3Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milano; 4Rheumatology Unit, Department of Medicine, University of Padua, Padova; 5Department of Internal Medicine and Therapeutics, University of Pavia, Pavia; 6Rheumatology and Clinical Immunology, Department of Clinical and Experimental Sciences, University of Brescia, Brescia; 7Section of Rheumatology, Department of Medical Sciences, University of Ferrara; AOU Sant'Anna, Ferrara; 8Rheumatology Unit, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari; 9Department of Precision Medicine, University of Campania Luigi Vanvitelli, Napoli; 10Rheumatology Unit, Dept. of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Roma; 11Division of Rheumatology, Department of Medicine, Azienda Sanitaria Universitaria del Friuli Centrale, Udine; 12Internal Interdisciplinary Medicine Unit, Department of Experimental and Clinical Medicine, University of Florence, Firenze; 13Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona; 14Azienda Ospedaliero-Universitaria di Bologna, Internal Medicine and Rheumatology, IRCCS S. Orsola Malpighi, Bologna; 15Academic Rheumatology Centre, Department of Clinical and Biological Sciences, University of Turin; AO Mauriziano, Torino; 16Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, Bari; 17Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, Tor Vergata University of Rome, Roma; 18Clinical Rheumatology, ASST Gaetano Pini CTO; Department of Clinical Sciences and Community Health, University of Milano, Milano; 19Department of Clinical and Molecular Medicine, Sapienza University of Rome; AOU Sant'Andrea, Roma, Italy; 20Italian REVEAL Study Group Italy, Italy
156 -
S13:5 | Association between vasoactive-vasodilating therapy and reduced detection of pulmonary arterial hypertension in systemic sclerosis: evidence from a European Scleroderma Trials and Research study Nicola Farina1, Silvia Bellando-Randone1, Sebastien Sanges2, Hilde Jenssen Bjørkekjær3, Lorenzo Tofani4, Marie-Elise Truchetet5, Vanessa Smith6, Andra Balanescu7, Christina Bergmann8, Yannick Allanore9, Philipp Klemm10, Simona Truglia11, Luca Idolazzi12, Christopher Denton13, Roberta Foti14, Anna Wojteczek15, Emmanuel Chatelus16, Madelon Vonk17, Serena Guiducci1, David Launay2, Eric Hachulla2, Jeska De Vries-Bouwstra18, Anna-Maria Hoffmann-Vold19, Oliver Distler20, Marco Matucci-Cerinic1, Cosimo Bruni1. | 1Department of Experimental and Clinical Medicine, Scleroderma Unit, Division of Rheumatology, University of Florence, Az, Firenze, Italy; 2Univ. Lille, Inserm, CHU Lille, Department of Internal Medicine and Clinical Immunology, Reference Center for Rare Autoi, Lille, France; 3Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway; 4Department of Statistics, Informatics and Applications, University of Florence, Firenze, Italy; 5Rheumatology department, CHU de Bordeaux, Bordeaux, France; 6University of Ghent, Department of Rheumatology, Gent, Belgium; 7Department of Rheumatology, St. Maria Hospital, Carol Davila, University of Medicine and Pharmacy Bucharest Romania; 8Department Internal Medicine 3, University Hospital Erlangen, Erlangen, Germany; 9Rheumatology Department, Université Paris Cité, Cochin Hospital, Paris, France; 10Department of Rheumatology and Clinical Immunology Center, JLU Giessen, Campus Kerckhoff Bad Nauheim Germany; 11Reumatologia, Azienda Ospedaliero-Universitaria Policlinico Umberto I, Roma, Italy; 12Section of Rheumatology, Department of Medicine, University of Verona, Verona, Italy; 13Centre for Rheumatology, Royal Free London and University College London Medical School, London, United Kingdom; 14Division of Rheumatology, A.O.U. Policlinico-San Marco, Catania, Italy; 15Department of Rheumatology, Clinical Immunology, Geriatrics and Internal Medicine, Medical University of Gdansk, Univers Gdansk Poland; 16Department of Rheumatology, University Hospital Strasbourg Strasbourg France; 17Department of rheumatology, Radboud University Nijmegen Medical Center Nijmegen The Netherlands; 18Department of Rheumatology, Leiden University Medical Center Leiden The Netherlands; 19Department of Rheumatology, Oslo University Hospital, Oslo, Norway; 20Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
123 -
PO:32:178 | Effectiveness of oral anticoagulants in precapillary pulmonary hypertension associated with systemic sclerosis: a EUSTAR cohort study Nicola Farina1, Silvia Bellando-Randone1, Hilde Jenssen-Bjørkekjær2, David Launay3, Patricia Carreira4, Paolo Airò5, Serena Guiducci1, Dilia Giuggioli6, Gabriela Riemekasten7, Carmen-Pilar Simeón Aznar8, Christina Bergmann9, Elise Siegart10, Ivan Castellví11, Lesley Ann Saketkoo12, Jeska De Vries-Bouwstra13, Philipp Klemm14, Ulf Müller-Ladner14, Alexandra Balbir-Gurman15, Vanessa Smith16, Florenzo Iannone17, Luca Idolazzi18, Christopher Denton19, Edoardo Rosato20, Britta Maurer1, Yannick Allanore1, Yoshiya Tanaka1, Elisabetta Zanatta1, Oliver Distler1, Marco Matucci-Cerinic1, Cosimo Bruni1 | 1Department of Experimental and Clinical Medicine, Scleroderma Unit, Division of Rheumatology, University of Florence, Az Firenze, Italy; 2Department of Rheumatology, Hospital of Southern Norway Kristiansand, Norway; 3National Reference Center for Pulmonary Arterial Hypertension Pulmotension Lille, France; 4Hospital Universitario 12 de Octubre, Rheumatology Department Madrid Spain; 5ASST Spedali Civili of Brescia, University of Brescia, Rheumatology and Clinical Immunology Unit Brescia, Italy; 6Scleroderma Unit, Rheumatology Unit, University Hospital of Modena and Reggio Emilia Modena, Italy; 7Universitätsklinikum Schleswig-Holstein, Klinik für Rheumatologie und klinische Immunologie Lübeck Germany; 8Hospital Universitario Vall d'Hebron, Department of Internal Medicine, Systemic Autoimmune Diseases Unit Barcelona Spain; 9University Hospital Erlangen, Department Internal Medicine 3 Erlangen Germany; 10Charité University Hospital, Department of Rheumatology Berlin Germany; 11Hospital de la Santa Creu i Sant Pau Baercelona Spain; 12New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center New Orleans, USA; 13Leiden University Medical Center, Department of Rheumatology Leiden, The Netherlands; 14JLU Giessen, Campus Kerckhoff, Department of Rheumatology and Clinical Immunology Center Bad Nauheim Germany; 15Rambam Health Care Campus, Rheumatology Institute Haifa, Israel; 16University of Ghent, Department of Rheumatology Ghent, Belgium; 17Rheumatology DiMePReJ, University of Bari, School of Medicine Bari, Italy; 18University of Verona, Section of Rheumatology, Department of Medicine Verona, Italy; 19Royal Free London and University College London Medical School, Centre for Rheumatology London, United Kingdom; 20Sapienza University of Rome, Department of Translational and Precision Medicine Azienda Ospedaliero-Universitaria Policl Roma, Italy
15 -
PO:31:175 | Characterizing gastrointestinal involvement in systemic sclerosis: insights from the national systemic sclerosis progression investigation registry of the Italian Society of Rheumatology Francesco Bonomi1, Cosimo Bruni1|2, Silvia Laura Bosello3, Fabio Cacciapaglia4|5, Corrado Campochiaro6, Roberto Caporali7, Veronica Codullo8, Maria Antonietta D'Agostino3, Lorenzo Dagna6, Rossella De Angelis9, Giacomo De Luca6, Dilia Giuggioli10, Serena Guiducci1, Florenzo Iannone4, Francesca Ingegnoli7, Carlomaurizio Montecucco8, Valeria Riccieri11, Clodoveo Ferri10, Marco Matucci Cerinic6, Silvia Bellando Randone1. | 1Scleroderma Unit, Division of Rheumatology AOUC, and Department of Experimental and Clinical Medicine, Uni. of Florence, Firenze, Italy; 2Department of Rheumatology, University Hospital Zurich, University of Zurich Zurigo Switzerland; 3UOC of Rheumatology and Clinical Immunology, Catholic University of the Sacred Heart, Fondazione Policlinico A. Gemelli, Roma, Italy; 4Rheumatology Unit, Department of Emergency Surgery and Organ Transplantations, University of Bari, Bari, Italy; 5Rheumatology Service, F. Miulli General Hospital - Department of Medicine and Surgery, LUM 'G. De Gennaro', Casamassima, Italy; 6Unit of Immunology, Rheumatology, Allergy and Rare Diseases and Inflammation, fibrosis and ageing initiative, UniSR, Milano, Italy; 7Division of Clinical Rheumatology, ASST Pini and Università degli studi di Milano, Milano, Italy; 8Department of Rheumatology, Policlinico San Matteo, Pavia, Italy; 9Rheumatology Unit, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy; 10Rheumatology Unit, School of Medicine, University of Modena and Reggio Emilia, Modena, Italy; 11Department of Rheumatology, Sapienza University of Rome, Roma, Italy.
149 -
PO:31:165 | Prevalence and incidence of skin telangectasia and their association with clinical features: analysis of the European Scleroderma Trials and Research cohort Gemma Lepri1, Lorenzo Tofani2, Silvia Bellando Randone1, Veronica Batani3, Paolo Airò4, Patricia Carreira5, Joerg Henes6, Alexandra Balbir Gurman7, Florenzo Iannone8, Antonella Marcoccia9, Luc Mouthon10, Branimir Anic11, Carolina De Souza Müller12, Armine Haroyan13, Ana Cristina Cordeiro14, Serena Guiducci And Eustar Coll1. | 1University of Florence, Dept of Experimental and Clinical Medicine, AOU Careggi, Division of Rheumatology Florence Italy; 2University of Florence, Dept of Statistics, Informatics, Applications, Florence, Italy; 3Unit of Immunology, Rheumatology, Allergy and Rare Diseases UnIRAR, IRCCS San Raffaele, Milano, Italy; 4Scleroderma Unit, UOC Rheumatology and Clinical Immunology, ASST Spedali Civili, Brescia, Italy; 5Dept of Rheumatology, 12 de Octubre University Hospital, Madrid, Spain; 6Centre for Interdisciplinary Rheumatology, Immunology and autoimmune diseases INDIRA, University Hospital Tuebingen, Tuebingen, Germany; 7Rheumatology Institute, Rambam Health Care Campus Haifa Israel; 8Dept of Precision and Regenerative Medicine and Ionian Area, University of Bari, Bari, Italy; 9Interdisciplinary Reference Center for Systemic Sclerosis CRIIS Sandro Pertini Hospital, Rome, Italy; 10Dept of Internal Medicine, Cochin Hospital, Paris Cité University, Paris, France; 11Div Clinical Immunology and Rheumatology, Dept Internal Medicine, School of Medicine, University Hospital Center Zagreb, Zagreb, Croatia; 12Rheumatology Division, Hospital de Clínicas da Universidade Federal do Parana, Curitiba, Brazil; 13Dept of Rheumatology, Yerevan State Medical University of Armenia, Yerevan, Armenia; 14Servico Reumatologia Hospital Garcia de Orta Almada, Almada, Portugal.
148 -
PO:33:190 | Travel distance to tertiary healthcare reflects disease severity and medication access in systemic sclerosis patients: insights from the Italian systemic sclerosis progression investigation registry of the Italian Society of Rheumatology Camilla Teresa Magnanimi1, Enrico De Lorenzis1, Gerlando Natalello1, Fabio Cacciapaglia2, Rossella De Angelis3, Edoardo Cipolletta3, Maria Antonietta D'Agostino1, Veronica Cudullo4, Giacomo De Luca5, Dilia Giuggioli6, Francesca Ingegnoli7, Valeria Riccieri8, Lorenzo Dagna5, Fiorenzo Iannone9, Clodoveo Ferri6, Marco Matucci Cerinic5, Silvia Laura Bosello1. | 1Division of Rheumatology and Clinical Immunology, Catholic University of the Sacred Heart, Fondazione Policlinico Univer, Roma, Italy; 2Department of Medicine and Surgery, LUM University Giuseppe De Gennaro Casamassima e Rheumatology Service Miulli Ge, Bari, Italy; 3Rheumatology Unit - Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy; 4Department of Rheumatology, Policlinico San Matteo, Pavia, Italy; 5Unit of Immunology, Rheumatology, Allergy and Rare Diseases UnIRAR, IRCCS San Raffaele Scientific Institute, Vita-Salu, Milano, Italy; 6Rheumatology Unit, School of Medicine, University of Modena and Reggio Emilia, Modena, Italy; 7Division of Clinical Rheumatology, ASST Pini, Dept. of Clinical Sciences e Community Health, Research Center for Adult a, Milano, Italy; 8Department of Rheumatology, La Sapienza University of Rome, Roma, Italy; 9Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, Bari, Italy.
153 -
PO:31:172 | Age and timing of onset of Raynaud's phenomenon and first non-Raynaud sign/symptom as prognostic factors in systemic sclerosis: a retrospective analysis from the systemic sclerosis progression investigation registry of the Italian Society for Rheumatology Silvia Peretti1, Cosimo Bruni2, Silvia Laura Bosello3, Fabio Cacciapaglia4-5, Corrado Campochiaro6-7, Veronica Codullo8, Lorenzo Dagna6-7, Rossella De Angelis9, Giacomo De Luca6-7, Dilia Giuggioli10, Serena Guiducci1, Florenzo Iannone4, Francesca Ingegnoli11, Valeria Riccieri12, Marco Matucci Cerinic6-7, Clodoveo Ferri10-13, Silvia Bellando Randone1. | 1Division of Rheumatology, Scleroderma Unit, Department of Experimental and Clinical Medicine, University of Florence, AO, Firenze, Italy; 2Division of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; 3Rheumatology Division, Catholic University of the Sacred Heart, Fondazione Policlinico Universitario A. Gemelli- IRCCS, Roma, Italy; 4Rheumatology Unit, Department of Precision and Regenerative Medicine-Ionian Area, University of Bari Aldo Moro, Bari, Italy; 5Reumatology Service, Internal Medicine Unit F.Miulli General Hospital, Acquaviva delle Fonti -Department of Medicine a, Bari, Italy; 6Unit of Immunology, Rheumatology, Allergy and Rare Diseases UnIRAR, Inflammation, Fibrosis and Ageing initiative INFL, Milano, Italy; 7Vita-Salute San Raffaele University, Milano, Italy; 8Department of Internal Medicine and Therapeutics, Università di Pavia, Italy; Division of Rheumatology, Fondazione IRCCS, Pavia, Italy; 9Rheumatology Unit, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy; 10Rheumatology Unit, School of Medicine, University of Modena and Reggio Emilia, Modena, Italy; 11Division of Clinical Rheumatology, ASST Pini, Dept. of Clinical Sciences and Community Health, Research Center for Adul, Milano, Italy; 12Department of Rheumatology, Sapienza University of Rome, Roma, Italy; 13Rheumatology Clinic Madonna dello Scoglio Crotonei, Crotone, Italy.
150 -
PO:01:003 | Sex-based differences in 2 years treatment outcomes with b/ts-DMARDs in psoriatic arthritis: from real-world evidence to predictive modeling from the Gruppo Italiano Studio Early Arthritis (GISEA) prospective registry Simone Perniola1, Florenzo Iannone1, Francesco Paolo Cantatore2, Angelo Semeraro3, Leonardo Santo4, Roberto Gorla5, Alberto Cauli6, Roberto Felice Caporali7, Bruno Frediani8, Rosario Foti9, Fabrizio Conti10, Marco Sebastiani11, Maria Sole Chimenti12, Roberta Ramonda13, Fabiola Atzeni14, Maurizio Rossini15, Serena Bugatti16, Serena Guiducci17, Giovanni Lapadula1, Gianfranco Ferraccioli18, Francesca Romana Spinelli10, Elisa Gremese19. | 1Rheumatology Unit, DiMePReJ, University of Bari, Bari; 2Rheumatology Unit, Department of Medical and Surgical Sciences, Azienda Ospedaliero-Universitaria Policlinico Riuniti, Foggia; 3Rheumatology Unit, Martina Franca Hospital; 4Rheumatology Unit, ASL BT, P.O. Barletta; 5Rheumatology and Clinical Immunology Unit, ASST Spedali Civili of Brescia; 6Rheumatology Unit, Department of Medical Science and Public Health, University of Cagliari, Monserrato (CA); 7Rheumatology Unit, Dipartimento di Reumatologia e Scienze Mediche, ASST PINI-CTO, University of Milano, Milano; 8Rheumatology Unit, Azienda Ospedaliero Universitaria Senese, Siena; 9Rheumatology Unit, A.O.U. Policlinico S. Marco, Catania; 10Rheumatology Unit, Department of Clinical Internal, Anesthesiologic and CV Sciences, Sapienza University of Rome, Roma; 11Rheumatology Unit, AUSL Piacenza, University of Parma, Parma; 12Rheumatology, Department of Systems Medicine, University of Rome Tor Vergata, Roma; 13Rheumatology Unit, DIMED, University of Padua, Padova; 14Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina, Messina; 15Rheumatology Unit, Department of Medicine, University of Verona, Verona; 16Division of Rheumatology, Dept. of Internal Medicine and Therapy, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia; 17Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Firenze, Firenze; 18Department of Medicine, Catholic University of the Sacred Heart, Fondazione Policlinico Gemelli IRCCS, Roma; 19Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, Humanitas University, Rozzano (MI), Italy
189 -
PO:06:079 | Weighing the burden: how body mass index shapes clinical outcomes in rheumatoid arthritis. Insights from a large Italian cohort Marco Capodiferro1, Marco Fornaro1, Gian Luca Erre2, Matteo Piga3, Elena Bartoloni Bocci4, Andreina Manfredi5, Ennio Giulio Favalli6, Maria Sole Chimenti7, Serena Guiducci8, Eleonora Celletti9, Addolorata Corrado10, Alessandro Giollo11, Simone Parisi12, Ivan Giovannini13, Elisa Gremese14, Garifallia Sakellariou15, Ombretta Viapiana16, Fabiola Atzeni17, Francesca Romana Spinelli18, Fabio Cacciapaglia1|19. | 1Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area DiMePRe-J University of Bari, Bari, Italy; 2Dipartimento di Scienze Mediche, Chirurgiche e Sperimentali, Università degli Studi di Sassari, Sassari, Italy; 3Rheumatology Unit, AOU Cagliari, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy; 4Rheumatology Unit, Department of Medicine and Surgery, University of Perugia, Perugia, Italy; 5Rheumatology Unit, Azienda Ospedaliera Universitaria Policlinico of Modena, Modena, Italy; 6Dpt of Rheumatology, G. Pini Institute, Milano, Italy; 7Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy; 8Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, Firenze, Italy; 9Rheumatology Unit, SS Annunziata Hospital, Chieti, Italy; 10Rheumatology Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy; 11Rheumatology Unit, Department of Medicine, University of Padova Hospital Trust, Padova, Italy; 12Rheumatology Department, A.O.U. Città della Salute e della Scienza, Torino, Italy; 13Rheumatology Department, Santa Maria della Misericordia Hospital, Udine, Italy; 14Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, Rozzano (MI), Italy; 15Department of Internal Medicine and Therapeutics, University of Pavia, Istituti Clinici Scientifici Maugeri, Pavia, Italy; 16Rheumatology Unit, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy; 17Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina, Messina, Italy; 18Reumatology Unit, Department of Internal, Anesthesiological, and Cardiovascular Clinical Sciences, Sapienza University, Roma, Italy; 19Miulli General Hospital Acquaviva - Department of Medicine and Surgery, LUM F. De Gennaro University, Casamassima (BA), Acquaviva delle Fonti (BA), Italy.
159 -
PO:19:279 | Predictors of proteinuria, amyloidosis and kidney failure in familial Mediterranean fever: data from the International AIDA Network Registry Jessica Sbalchiero1, Antonio Vitale1, Valeria Caggiano1, Abdurrahman Tufan2, Ezgi Batu3, Gaafar Ragab4, Seza Ozen3, Jurgen Sota1, Carla Gaggiano1, Ali Sahin5, Petros Sfikakis6, Francesca Li Gobbi7, Giacomo Emmi8, Jose Rodriguez9, Piero Ruscitti10, Paolo Sfriso11, Ewa Szewczyk12, Giuseppe Lopalco13, Alberto Balistreri14, Claudia Fabiani15, Bruno Frediani1, Luca Cantarini1 | 1Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy; 2Department of Internal Medicine, Division of Rheumatology, Gazi University Hospital Ankara, Turkey; 3Division of Pediatric Rheumatology, Department of Pediatrics, Hacettepe University School of Medicine Ankara, Turkey; 4Internal Medicine Department, Rheumatology and Clinical Immunology Unit, Faculty of Medicine, Cairo University Giza, Egypt; 5Division of Rheumatology, Department of Internal Medicine, Sivas Cumhuriyet University Medical Faculty Sivas, Turkey; 6Joint Academic Rheumatology Program, Medical School, National and Kapodistrian University of Athens Athens, Greece; 7Rheumatology Unit, Hospital S. Giovanni di Dio, Azienda USL-Toscana Centro Florence, Italy; 8Clinical Medicine and Rheumatology Unit, Cattinara University Hospital Trieste, Italy; 9Department of Autoimmune Diseases, Institut Investigacions Biomediques August Pi I Sunyer, University of Barcelona Barcelona Spain; 10Rheumatology Unit, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy; 11Rheumatology Unit, Department of Medicine, University of Padua Padua, Italy; 127Department of Internal Medicine, Pneumonology, Allergology, Clinical Immunology and Rare Diseases, Military Institute o Warsaw, Poland; 13Department of Precision and Regenerative Medicine and Ionian Area DiMePRe-J Policlinic Hospital, University of Bari Bari, Italy; 14Bioengineering and Biomedical Data Science Lab, Department of Medical Biotechnologies, University of Siena Siena, Italy; 15Ophthalmology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena Siena, Italy
32 -
CO:10:4 | Lung vasculature quantification on computed tomography predicts new onset of interstitial lung disease in systemic sclerosis Maria Iacovantuono1|2, Nicholas Landini2|3, Lisa Jungblut4, Gesa Sauer2, Rucsandra Dobrota2, Maria Sinziana Muraru-Carbune2, Muriel Elhai2, Carmen-Marina Mihai2, Mike Oliver Becker2, Maria Sole Chimenti1, Thomas Frauenfelder4, Anna-Maria Hoffmann-Vold5, Oliver Distler2, Cosimo Bruni2. | 1Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, Tor Vergata University, Rome, Italy; 2Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland; 3Department of Radiological Sciences, Oncology and Pathology, Sapienza University, Policlinico Umberto I, Rome, Italy; 4Institute for Diagnostic and Interventional Radiology, University Hospital Zurich, University Zurich, Switzerland; 5Department of Rheumatology, Oslo University Hospital, Norway
136 -
PO:35:221 | Cryofibrinogen: a cold case. Characteristics and clinical outcomes from a cryofibrinogen positive cohort Daniele Catameró1, Andrea Cito1, Cristiana Colaprico1, Teresa Caferri1, Teresa Troiano1, Anna Marinaccio1, Marco Fornaro1, Giuseppe Lopalco1, Florenzo Iannone1. | 1Unit of Rheumatology , Department of Precision and Regenerative Medicine, Area Jonica DiMePRe-J, University of Bari, Bari, Italy.
144 -
CO:01:4 | Identify predictors of relapse in idiopathic inflammatory myopathies: insights from an international cohort Cristina Bochicchio1|2, Maria Rosa Pellico1|2, Claudia Iannone1|2, Lekshmi Minikumari Rahulan3, Marco Fornaro4, Ilaria Cavazzana5, Edoardo Conticini6, Musataka Musataka7, Akira Yoshida7, Silvia Cavalli1|2, Silvia Grazzini6, Giulio Fraticelli8, Alessia Gatti5, Giulio Lopinto4, Paolo Semeraro5, Veronica Batani8, Thomas Patric Sheeran9, Florenzo Iannone4, Giacomo De Luca8, Roberto Caporali1|2, Latika Gupta9|10|11, Nicoletta Del Papa2. | 1Department of Clinical Sciences and Community Health, University of Milano; 2Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO Institute, Milano, Italy; 3Rheumatology "Sanjay Gandhi" Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India; 4Unit of Rheumatology, Department of Precision and Regenerative Medicine, Area Jonica, University of Bari; 5Rheumatology and Clinical Immunology Unit, ASST Spedali Civili di Brescia; 6Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Italy; 7Department of Allergy and Rheumatology Nippon Medical School Graduate School of Medicine, Tokyo, Japan; 8Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milano, Italy; 9Department of Rheumatology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, UK; 10Francis Crick Institute, London, UK; 11School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, UK
191 -
PO:35:219 | Real-world effectiveness of mepolizumab on gastrointestinal involvement in eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome: a multicentre retrospective study Alessia Gatti1, Francesca Regola1, Giulia Fontana1, Mario Addrea Piga2, Gianluca Moroncini2, Palma Carlucci3, Angelo Vacca3, Paolo Delvino4, Enrico Heffler5, Emanuele Nappi5, Jakub Moll6, Laura Losappio6, Jan Schroeder6, Federica Davanzo7, Roberto Padoan7, Edoardo Conticini8, Paolo Cameli8, Greta Pacini9, Alvise Berti9, Lorenzo Vrola10, Paola Tomietto10, Luca Quartuccio11, Jan Willem Cohen Tervaert12, Sabrina Arnold13, Peter Lamprecht13, Florence Roufosse14, Ilaria Cavazzana1, Franco Franceschini1, Giacomo Emmi15, Paola Toniati1. | 1Rheumatology and Clinical Immunology Unit, ERN ReCONNET, ASST Spedali Civili of Brescia and University of Brescia, Italy, Brescia, Italy; 2Università Politecnica delle Marche and Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy, Ancona, Italy; 3Section of Internal Medicine 'Guido Baccelli', DiMePRe-J, University of Bari 'Aldo Moro', Bari, Italy, Bari, Italy; 4Rheumatology Unit, IRCCS San Gerardo dei Tintori, Monza, Italy Monza Italy; 5Department of Biomedical Sciences, Humanitas University and Personalized Medicine, Asthma and Allergy IRCCS Humanitas, Milano, Italy; 6Division of Allergy and Clinical Immunology, ASST GOM Niguarda, Milan, Italy, Milano, Italy; 7Rheumatology Unit, Department of Medicine DIMED, University of Padua, Padova, Italy, Padova, Italy; 8University of Siena, Siena, Italy, Siena, Italy; 9Santa Chiara Hospital and University of Trento, Unit of Rheumatology, Trento, Italy Trento Italy; 10UCO Medicina Clinica, ASUGI, Cattinara Teaching Hospital, Trieste, Italy, Trieste, Italy; 11Division of Rheumatology, Department of Medicine DMED, University of Udine, Udine, Italy, Udine, Italy; 12University of Alberta, Edmonton, Alberta, Canada and Maastricht University, Maastricht, The Netherlands Maastricht The Netherlands; 13Department of Rheumatology and Clinical Immunology, University of Lübeck, Lübeck, Germany Lubeck Germany; 14Department of Internal Medicine, Hôpital Universitaire de Bruxelles - Erasme, Université Libre de Bruxelles, Belgium Brussels Belgium; 15Clinical Medicine and Clinical Immunology and Rheumatology Unit Cattinara University Hospital and University of Trieste, Trieste, Italy.
180 -
PO:02:022 | Bimekizumab Maintained Stringent Clinical Responses over 2 Years in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies Fabian Proft1, Désirée Van Der Heijde2, Sergio Schwartzman3|4|5, Joerg Ermann6, Alexander Marten7, Ute Massow7, George Stojan8, Vanessa Taieb9, Diana Voiniciuc10, Astrid Van Tubergen11, Victoria Navarro-Compán12, Simone Angioni13, Xenofon Baraliakos14 | 1Charité-Universitätsmedizin Berlin; Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; 2Department of Rheumatology, Leiden University Medical Center Leiden, The Netherlands; 3Weill Cornell Medical Center New York, USA; 4New York Presbyterian Hospital New York, USA; 5Hospital for Special Surgery New York, USA; 6Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital and Harvard Medical School Boston, USA; 7UCB Monheim am Rhein Germany; 8UCB Atlanta, USA; 9UCB Colombes, France; 10UCB Slough, United Kingdom; 11Department of Medicine, Division of Rheumatology, Maastricht University Medical Center Maastricht, The Netherlands; 12Department of Rheumatology, La Paz University Hospital, IdiPaz Madrid, Spain; 13UCB Milan, Italy; 14Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Germany
18 -
PO:02:016 | Real-world evidence of upadacitinib over two years in Italian patients with axial spondyloarthritis Mariagrazia Lorenzin1, Giacomo Cozzi1, Stefano Gentileschi2, Michele Maria Luchetti Gentiloni3, Antonio Carletto4, Maria Sole Chimenti5, Maria Manara6, Luca Quartuccio7, Rosario Foti8, Salvatore D'Angelo9, Ariela Hoxha10, Carlo Selmi11, Bernd Raffeiner12, Alessandro Giollo1, Alberto Cauli13, Carlo Salvarani14, Fabiola Atzeni15, Roberta Ramonda1, Sir Study Group Spa E Psa Antonio Spadaro16. | 1Rheumatology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy; 2Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy; 3Clinica Medica, Ospedali Riuniti Ancona University Hospital, Ancona; Department of Clinical and Molecular Sciences, Ancona, Italy; 4Rheumatology Unit, Department of Medicine, AOUI University of Verona, Verona, Italy; 5Rheumatology, allergology and clinical Immunology, Department of Systems Medicine, University of Rome Tor Vergata, Roma, Italy; 6Humanitas San Pio X, Milano, Italy; 7University of Udine, Academic Hospital Santa Maria della Misericordia, Udine, Italy; 8Rheumatology Unit, A.O.U. Policlinico S. Marco, Catania, Italy; 9Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy; 10Internal Medicine Unit, Thrombotic and Hemorrhagic Center, Department of Medicine-DIMED, University of Padua, Padova, Italy; 11Department of Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy; 12Department of Rheumatology, Teaching Hospital of the Paracelsius Medical Hospital of Bolzano ASAA-SABES, Bolzano, Italy; 13Rheumatology Unit, Department of Medical Sciences, AOU and University of Cagliari, Monserrato, Cagliari, Italy; 14Department of Rheumatology, Azienda USL-IRCCS di Reggio Emilia and Università di Modena and Reggio Emilia, Reggio Emilia, Italy; 15Rheumatology Unit, University of Messina, Messina, Italy; 16Società Italiana di Reumatologia, Milano, Italy.
166 -
PO:01:004 | Real-world retention of IL-17 inhibitors in psoriatic arthritis: impact of prior IL-17 exposure across multiple treatment lines in the “BIRRA” multicentre cohort Valentino Paci1, Alarico Ariani2, Eleonora Celletti3, Alberto Lo Gullo4, Camilla Mazzanti5, Valeria Nucera6, Natalia Mansueto7, Rosalba Caccavale8, Patrizia Del Medico9, Antonella Farina10, Palma Scolieri11, Cecilia Giampietro12, Olga Addimanda13, Riccardo Bixio14, Maddalena Larosa15, Viviana Ravagnani16, Federica Lumetti17, Aldo Biagio Molica Colella17, Elena Bravi17, Rosetta Vitetta17, Bernd Raffeiner17, Gilda Sandri18, Rosario Foti19, Simone Parisi20, Michele Maria Luchetti Gentiloni1, Gianluca Moroncini1. | 1Clinical Medicine, Department of Clinical and Molecular Sciences, Marche Polytechnic University, AOU delle Marche, Ancona, Italy; 2Internal Medicine and Rheumatology Unit, University Hospital of Parma, Parma, Italy; 3Rheumatology Unit, Clinica Medica Institute, Ospedale SS. Annunziata di Chieti, G.d'Annunzio University of Chieti, Chieti, Italy; 4Rheumatology Unit, ARNAS Garibaldi di Catania, Catania, Italy; 5Center for the Diagnosis and Therapy of Autoimmune Rheumagological Diseases, Ospedale Santa Rosa, ASL Viterbo Viterbo Italy; 6Rheumatology Outpatient Unit, ASL Novara, Novara, Italy; 7Ambulatori di Reumatologia ASL1 Liguria, Imperia Hospitall Imperia Italy; 8Department of Clinical, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Polo Pontino, Roma, Italy; 9Rheumatology outpatient clinic - Internal Medicine Unit, Civitanova Marche Hospital, Civitanova Marche, Italy; 10Internal Medicine Unit, Rheumatology outpatient clinic, Ospedale A. Murri di Fermo, Fermo, Italy; 11Department of Medical Specialties, Nuovo Regina Margherita Hospital, Rome, Roma, Italy; 12Rheumatology Outpatient Clinic, Azienda ULSS 6 Euganea, Padova, Padova, Italy; 13Rheumatology Unit, Azienda Unità Sanitaria Locale di Bologna -- Policlinico S.Orsola- AOU di Bologna, Bologna, Italy; 14Rheumatology Unit, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy; 15Division of Rheumatology - Medical Specialties Department, Ospedale La Colletta-Azienda Sanitaria Locale 3, Genova, Italy; 16Rheumatology Unit, Santa Chiara Hospital APSS Trento Italy; 17BIRRA - BIologic Retention Rate in chronic Arthritis - study group, Parma, Italy; 18Rheumatology Unit, University of Modena and Reggio Emilia, Modena, Italy; 19Rheumatology Unit, Policlinico San Marco Hospital, Catania, Italy; 20Rheumatology Department, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.
199 -
CO:08:5 | Clinical impact of anti-Ro52 antibodies in idiopathic inflammatory myopathies: insights from a multicenter Italian cohort Paola Bizioli1, Cesare Tomasi2, Francesca Bellisai3, Francesca Buzzulini4, Antonio Tonutti5|6, Angela Ceribelli5|6, Edoardo Conticini3, Anna Ghirardello7, Luca Iaccarino7, Danilo Villalta4, Franco Franceschini1, Ilaria Cavazzana1. | 1Rheumatology and Clinical Immunology Unit - ERN ReCONNET, ASST Spedali Civili of Brescia; 2Department of Clinical and Experimental Sciences, University of Brescia; 3Department of Medicine, Surgery and Neurosciences, Rheumatology Unit, University of Siena; 4Department of Laboratory Immunology and Allergology, Santa Maria degli Angeli Hospital, Pordenone; 5Department of Biomedical Sciences, Humanitas University, Rozzano (MI); 6Rheumatology and Clinical Immunology, Istituti di Ricovero e Cura a Carattere Scientifico, Humanitas Research Hospital, Rozzano (MI); 7Division of Rheumatology, Department of Medical and Surgical Sciences, University of Padova, Italy
135 -
CO:06:3 | Clinical and laboratory markers for distinguishing VEXAS from Schnitzler's syndrome in male patients with skin involvement: insights from the International AIDA Network Registries Valeria Caggiano1, Jessica Sbalchiero1, Micol Frassi2, Andrea Hinojosa-Azaola3, Francesca Crisafulli2, Franco Franceschini2, Paolo Sfriso4, Sara Bindoli4, José Hernández-Rodríguez5, Henrique A. Mayrink Giardini6, Giuseppe Lopalco7, Florenzo Iannone7, Ombretta Viapiana8, Amato De Paulis9, Lorenzo Dagna10, Antonio Gidaro11, Serena Bugatti12, Matteo Piga13, Fabrizio Conti14, Rosetta Vitetta15, Cecilia Chighizola16, Marcello Govoni17, Giacomo Emmi18, Paola Triggianese19, Carmelo Gurnari19, Bruno Frediani1, Claudia Fabiani1, Luca Cantarini1, Antonio Vitale1, for the AIDA Network1 | 1Department of Medical Sciences, Surgery and Neurosciences, University of Siena; 2University of Brescia, Italy; 3Department of Immunology and Rheumatology, Mexico City, Mexico; 4Rheumatology Unit, University of Padova, Italy; 5Clinical Unit of Autoinflammatory Diseases, Hospital Clínic of Barcelona, Spain; 6Rheumatology Division, Universidade de São Paulo, Brazil; 7University of Bari; 8Rheumatology Unit, University and Azienda Ospedaliera Universitaria Integrata of Verona; 9University of Napoli "Federico II"; 10Università Vita-Salute San Raffaele, Milano; 11Luigi Sacco Hospital, University of Milano; 12Università di Pavia; 13University and AOU of Cagliari; 14AOU Policlinico Umberto I, Sapienza University of Rome; 15Unit of Rheumatology, ASL Sant' Andrea Hospital, Vercelli; 16University of Milano; 17Azienda Ospedaliero-Universitaria S. Anna, Ferrara; 18University of Trieste; 19University of Rome-Tor Vergata, Rome, Italy.
196 -
PO:33:199 | Prevalence and clinical associations of antiphospholipid antibodies in patients with systemic sclerosis in the SPRING-SIR registry Antonio Tonutti1|2, Ilaria Cavazzana3, Angela Ceribelli1|2, Maria De Santis1|2, Giacomo De Luca4|5, Maria Grazia Lazzaroni3, Franco Franceschini3, Carlo Selmi1|2, Valeria Riccieri6, Silvia Laura Bosello7, Fabio Cacciapaglia8, Veronica Codullo9, Francesca Ingegnoli10, Dilia Giuggioli11, Rossella De Angelis12, Clodoveo Ferri11, Marco Matucci-Cerinic4|5 | 1Department of Biomedical Sciences, Humanitas Universityce Pieve Emanuele, Milan, Italy; 2Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital Rozzano, Milan, Italy; 3Rheumatology and Clinical Immunology - ASST Spedali Civili Brescia - Department of Clinical and Experimental Sciences - Brescia, Italy; 4Vita-Salute San Raffaele University Milan, Italy; 5Unit of Immunology, Rheumatology, Allergy and Rare Diseases UnIRAR and INFLAGE Initiative, IRCCS San Raffaele Hospital Milan, Italy; 6University of Rome La Sapienza Rome, Italy; 7Catholic University of Sacred Heart Rome, Italy; 8LUM University Bari, Italy; 9Rheumatology Unit, Fondazione IRCCS Policlinico San Matteo Pavia, Italy; 10University of Milan Milan, Italy; 11University of Modena and Reggio Emilia Modena, Italy; 12Politechnic University of Marche Ancona, Italy
14 -
PO:14:193 | Dapirolizumab Pegol Demonstrated Significant Improvement in Systemic Lupus Erythematosus Disease Activity: Efficacy and Safety Results of a Phase 3 Trial Megan EB Clowse1, Marta Mosca2, David A Isenberg3, Joan T Merrill4, Thomas Dörner5, Michelle Petri6, Edward M Vital7|8, Eric F Morand9, Teri Jimenez10, Stephen Brookes11, Janine Gaiha-Rohrbach12, Christophe Martin13, Annette Nelde14, Christian Stach15 | 1Duke University - Division of Rheumatology and Immunology Durham, USA; 2University of Pisa - Rheumatology Unit, Department of Clinical and Experimental Medicine Pisa, Italy; 3University College London - Department of Ageing, Rheumatology and Regenerative Medicine, Division of Medicine London, United Kingdom; 4Oklahoma Medical Research Foundation Oklahoma City, USA; 5Charité Universitätsmedizin Berlin - Department of Medicine/Rheumatology and Clinical Immunology Berlin Germany; 6Johns Hopkins University School of Medicine Baltimore, USA; 7University of Leeds - Leeds Institute of Rheumatic and Musculoskeletal Medicine Leeds, United Kingdom; 8Leeds Teaching Hospitals NHS Trust - NIHR Leeds Biomedical Research Centre Leeds, United Kingdom; 9Monash University - Centre for Inflammatory Diseases Melbourne, Australia; 10UCB Raleigh, USA; 11Biogen Maidenhead, United Kingdom; 12Biogen Cambridge, USA; 13UCB Slough, United Kingdom; 14Biogen Baar, Switzerland; 15UCB Monheim am Rhein, Germany
40 -
PO:23:046 | Histopathological comparison between minor salivary gland biopsies from pediatric and adult patients with Sjögren’s disease: evidence of a more severe inflammatory profile in early-onset cases Flavia Riccio1, Mattia Neri2, Martina Mellone1, Immacolata Cozzolino3, Jacopo Ferro4, Valerio Gaetano Vellone4, Ciro Emiliano Boschetti5, Giuseppe Colella5, Nicola Laffi6, Pietro Buono7, Enrico Tirri8, Renato Franco3, Marco Gattorno2, Francesco Ciccia1, Clara Malattia2, Saviana Gandolfo8 | 1UOC di Reumatologia, Università degli Studi della Campania Luigi Vanvitelli, Napoli; 2UOC di Reumatologia e Malattie Autoinfiammatorie, Istituto Giannina Gaslini, Genova; 3UO di Anatomia Patologica, Università degli Studi della Campania Luigi Vanvitelli, Napoli; 4UOC di Anatomia Patologica, Istituto Giannina Gaslini Genova; 5UOC di Chirurgia Maxillo-facciale, Università degli Studi della Campania Luigi Vanvitelli, Napoli; 6UO di Odontoiatria, Istituto Giannina Gaslini, Genova; 7UOD Attività consultoriali e assistenza materno-infantile, Direttorato Generale per la Salute, Regione Campania, Napoli; 8UO di Reumatologia, Ospedale del Mare, Napoli, Italy
163 -
PO:05:066 | Atypical diagnosis and manifestation of spondyloarthritis: a case report Adele Del Giudice1, Filippo Crescentini2, Giorgia Citriniti2, Luca Cimino1|3, Carlo Salvarani1|2 | 1Department of Rheumatology, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy; 2Department of Medicine, University of Melbourne at St Vincent's Hospital Melbourne, Australia; 3Department of Rheumatology, Division of Medicine, University College, London, UK
115 -
PO:16:232 | Belimumab step-down dose spacing in patients with systemic lupus erythematosus in persistent clinical remission: experience from a multicentric cohort Alice Bartoletti1, Laura Giudice1, Lorenza Maria Argolini1|2, Giuseppe Alvise Ramirez3, Luca Moroni3, Tommaso Schioppo4, Chiara Bellocchi5|6, Annalaura Fasiello6, Lorenzo Beretta6, Lorenzo Dagna3, Roberto Caporali1, Maria Gerosa1. | 1UO Clinica Reumatologica, ASST Gaetano Pini CTO, Milano, Italy; 2UOC Medicina fisica e riabilitazione specialistica, ASST Gaetano Pini CTO, Milano, Italy; 3Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Vita-Salute San Raffa Milano Italy; 4Medicina Generale II, Servizio di Reumatologia, Ospedale San Paolo, ASST Santi Paolo Carlo, Milano, Italy; 5Department of Clinical Sciences and Community Health, University of Milan, Dipartimeto di Eccellenza 2023-2027, Milano, Italy; 6Referral Centre for Systemic Autoimmune DIseases, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano, Italy
162 -
PO:06:093 | Clinical and ultrasound phenotyping comparison between Difficult-To-Treat Rheumatoid Arthritis (D2TRA) and non-D2TRA patients: experience from a monocentric cohort Silvia Perrone1, Claudio Cruciani1, Silvia Mascolo1, Elisa Bellis1, Gloria Crepaldi1, Valeria Data1, Claudia Garulli1, Claudia Lomater1, Elena Marucco1, Marta Saracco1, Mariele Gatto1, Annamaria Iagnocco1. | 1Academic Rheumatology Centre, Department of Clinical and Biological Sciences, University of Turin, AO Mauriziano, Turin, Italy.
124 -
PO:02:017 | Difficult-to-treat psoriatic arthritis: clinical and ultrasonographic predictors in a real-life cohort Federico Favaro1, Elisa Bellis1, Claudio Cruciani1, Gloria Crepaldi1, Valeria Data1, Claudia Garulli1, Claudia Lomater1, Elena Marucco1, Marta Saracco1, Mariele Gatto1, Annamaria Iagnocco1. | 1Academic Rheumatology Centre, Departement of Clinical and Biological Sciences, University of Turin, AO Mauriziano, Torino, Italy.
143 -
S05:6 | Prevalence of osteoporosis and bone mineral metabolism disorders in an Italian cohort of patients with microcrystalline arthritis: results from the PREMIA observational study of the Italian Society of Rheumatology Silvia Grignaschi1, Sonia Farah2, Silvia Balduzzi1, Bernd Raffeiner3, Carlomaurizio Montecucco4, Fausto Salaffi2, Enrico Selvi5, Annamaria Iagnocco6, Fabiola Atzeni7, Serena Guiducci8, Rosario Foti9, Maria Manara10, Marcello Govoni11, Carlo Selmi12, Francesca Oliviero13, Roberta Ramonda13 | 1ASST Pavia; 2Ospedale Carlo Urbani Jesi Italy; 3Azienda Sanitaria dell'Alto Adige, Bolzano; 4IRCCS Fondazione Policlinico San Matte, Pavia; 5AOU Senese, Siena; 6Ospedale MAuriziano, Torino; 7Università di Messina; 8AOU Careggi, Firenze; 9AOU Policlinico G. Rodolico, Catania; 10ASST Gaetano Pini-CTO Milano; 11AUSL Ferrara; 12Humanitas San Pio X, Milano; 13AOU Padova, Italy
135 -
PO:35:228 | Polymyalgia rheumatica and giant cell arteritis induced by immune checkpoint inhibitors for cancer treatment: a systematic review and meta-analysis highlighting differences from the idiopathic forms Elvis Hysa1, Andrea Casabella2, Emanuele Gotelli1, Rosanna Campitiello1, Carlo Genova3, Enrica Teresa Tanda4, Carmen Pizzorni1, Alberto Sulli1, Vanessa Smith5, Marco Amedeo Cimmino6, Sabrina Paolino1, Maurizio Cutolo1. | 1Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, Genova, Italy; 2IRCCS Ospedale Policlinico San Martino, Genova, Italy; 3Academic Oncology Unit; IRCCS Ospedale Policlinico San Martino, Genova, Italy; 4UOC Medical Oncology Clinic 2, Department of Internal Medicine, University of Genova, Genova, Italy; 5Department of Internal Medicine, Ghent University, Department of Rheumatology, Ghent University Hospital, Ghent, Belgium; 6Rheumatology Outpatient Clinic, Villa Ravenna Chiavari Italy.
141 -
PO:26:096 | From free text to diagnosis: a Natural Language Processing approach for identifying rheumatoid and psoriatic arthritis in the Emergency Department Antonio Tonutti1|2, Pierandrea Morandini3, Cosimo Faeti3, Nicoletta Luciano1|2, Saverio D'Amico3, Antonio Voza1|4, Victor Savevski3, Carlo Selmi1|2 | 1Department of Biomedical Sciences, Humanitas University Pieve Emanuele, Milan, Italy; 2Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital Rozzano, Milan, Italy; 3Artificial Intelligence Unit, IRCCS Humanitas Research Hospital Rozzano, Milan, Italy; 4Emergency Department, IRCCS Humanitas Research Hospital Rozzano, Milan, Italy
27 -
PO:31:174 | Increased frequency of anti-RNA polymerase 3 antibodies in patients with systemic sclerosis and silicone breast implants: a multicentre study from the international European Scleroderma Trials and Research cohort Maria Grazia Lazzaroni1, Yolanda Braun-Moscovici2, Elda Piovani1, Claudia Barison1, Liala Moschetti1, Veronica Batani3, Corrado Campochiaro3, Michal Tomcik4, Francesca Motta5, Maria De Santis5, Petros P. Sfikaki6, Masataka Kuwana7, Brigitte Granel8, Roberta Foti9, Virginia Berlingiero10, Joana Caetano11, Yannick Allanore12, Alexandra Balbir-Gurman2, Marco Matucci Cerinic3, Franco Franceschini1, Paolo Airò1. | 1ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy; 2Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion-Israeli Institute of Tecnology, Haifa, Israel; 3Vita-Salute San Raffaele University, San Raffaele Hospital, Milano, Italy; 4Institute of Rheumatology, Praga, Czech Republic; 5IRCCS Humanitas Research Hospital; Humanitas University, Milano, Italy; 6Joint Rheumatology Program, Medical School, National Kapodistrian University of Athens Atene GREECE; 7Nippon Medical School Hospital Tokyo Japan; 8Hôpital Nord de Marseille; Aix-Marseille Université Marsiglia France; 9AOU Policlinico G. Rodolico San Marco, Catania, Italy; 10Azienda Ospedaliera Universitaria Senese, Siena, Italy; 11Fernando Fonseca Hospital, Amadora, Portugal; 12Université Paris Cité, Cochin Hospital, Parigi, France.
140 -
PO:07:108 | Achievement of Treatment Targets and Maintenance of Response with Upadacitinib in Patients with Moderate-to-Severe Rheumatoid Arthritis in a Real-world Setting: Final 2-year Outcomes from the UPHOLD Study Enrico Marchetta1, Andrew Östör2|8, Eugen Feist3, Prodromos Sidiropoulos4, Jérôme Avouac5, Martin Rebella6|7, Rajaie Namas9, Erin Mcdearmon Blondell10, Ivan Lagunes10, Tianming Gao10, Tim Shaw10, Suzan Attar11 | 1AbbVie Srl Roma, Italy; 2Monash University and Emeritus Research, Melbourne, Victoria, Melbourne, Australia; 3Helios Department of Rheumatology and Clinical Immunology, Vogelsang-Gommern, Vogelsang Gommern, Germany; 4Faculty of Medicine, University of Crete, Heraklion, Heraklion, Greece; 5Service de Rhumatologie, Hôpital Cochin, AP HP Centre Université Paris Cité, Parigi, France; 6Departamento de Medicina, Facultad de Medicina, Universidad de la República, Montevideo, Montevideo, Uruguay; 7Unidad de Enfermedades Autoinmunes Sistémicas, MUCAM, Montevideo, Montevideo, Uruguay; 8Australian National University, Camberra, Australia; 9Medical Subspecialties Institute, Division of Rheumatology, Cleveland Clinic Abu Dhabi, United Arab Emirates; 10AbbVie Inc., North Chicago, Illinois, United States of America Chicago, USA; 11King Abdulaziz University, Jeddah, Saudi Arabia
21 -
PO:36:246 | Early real-world outcomes with benralizumab in eosinophilic granulomatosis with polyangiitis: a monocentric retrospective Richard Borrelli1, Stefania Nicola1, Federica Corradi1, Iuliana Badiu1, Marzia Boem1, Valentina Marmora1, Simone Negrini1, Luisa Brussino1. | 1SCDU Immunologia e Allergologia, AO Mauriziano, Dipartimento di Scienze Mediche, Università degli Studi di Torino, Torino, Italy.
137 -
PO:27:108 | Delphi consensus on the shared management of patients with rheumatologic and oncologic diseases Luigi De Marco1, Augusta Ortolan2, Antonio Carletto3, Fulvia Ceccarelli4, Lorenzo Dagna5, Ginevra De Marchi6, Ennio Giulio Favalli7, Alessandro Inno8, Giuseppe Lopalco9, Francesco Ciccia10, Ennio Lubrano11, Luca Quartuccio12, Immacolata Prevete13, Roberta Ramonda14, Nicola Silvestris15, Marcello Tiseo16, Michelina Turri1, Maria Sole Chimenti1 | 1Reumatologia, allergologia e immunologia clinica, dipartimento di medicina dei sistemi, Università di Roma Tor Vergata; 2UOC Reumatologia e immunologia clinica, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Roma; 3Unità di Reumatologia, Dipartimento di medicina, AOUI università di Verona; 4Reumatologia, Dipartimento di Scienze Cliniche, Anestesiologiche Internistiche e Cardiovascolari, Sapienza Università di Roma; 5Unità di Immunologia, Reumatologia, Allergologia e malattie rare UnIRar, IRCSS San Raffaele, Milano; 6Unità di Reumatologia, Dipartimento di medicina, Azienda Sanitaria Universitaria Integrata, Università di Udine; 7Dipartimento di Reumatologia e scienze mediche, Istituto Gaetano Pini, Università di Milano; 8Oncologia Medica, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella (VR); 9UOC Reumatologia, Dipartimento di Medicina di Precisione e Rigenerativa e Area Ionica, Università di Bari "Aldo Moro"; 10Unità di Reumatologia, Dipartimento di Medicina di Precisione, Università della Campania L. Vanvitelli, Napoli; 11Unità di Reumatologia, Università degli Studi del Molise, Campobasso; 12SOC Clinica Reumatologica - ASUFC, Dipartimento di Medicina, Università degli Studi di Udine; 13UOC Reumatologia Azienda Ospedaliera San Camillo-Forlanini, Roma; 14UOC di Reumatologia, Dipartimento di Medicina DIMED, Azienda Ospedale Università di Padova; 15UOC Oncologia Medica e Dipartimento Area Medica - IRCCS Istituto Tumori Giovanni Paolo II, Bari; 16UOC di Oncologia Medica, Azienda Ospedaliero-Universitaria di Parma, Italy
139 -
PO:35:234 | Sustained Vasculitis Quiescence and CS Reduction with Mepolizumab 100 mg Francesca Mascia1, Angelo Fassio2, Marco Zurlo1, Davide Chesini3, Francesco Pollastri2, Giovanni Adami2, Davide Gatti4, Maurizio Rossini4, Matteo Maule5, Gianentrico Senna1, Marco Caminati1 | 1University of Verona - Allergology and Clinical Immunology Verona, Italy; 2Policlinico G. B. Rossi - Rheumatology Verona, Italy; 3University of Verona - Faculty of Medicine and Surgery Verona, Italy; 4University of Verona - Rheumatology Verona, Italy; 5Policlinico G. B. Rossi - Allergology and Clinical Immunology Verona, Italy
15 -
PO:18:268 | Voclosporin as a Steroid-Sparing Agent in Lupus Nephritis Complicated by Central Serous Chorioretinopathy: A Case Report Irene Genovali1|2, Sebastiano Lorusso2, Damiano Currado1|2, Letizia Pia Di Corcia1, Ludovica Lamberti1, Annalisa Marino2, Antonio Orlando1, Maria Quadrini1, Marta Vadacca2, Marta Vomero1, Luca Navarini1|2, Roberto Giacomelli1|2 | 1Rheumatology and Clinical Immunology, Department of Medicine, University of Rome Campus Biomedico, School of Medicine Rome, Italy; 2Clinical and Research Section of Rheumatology and Clinical Immunology Fondazione Policlinico Campus Biomedico Rome, Italy
38 -
PO:26:087 | Rituximab versus glucocorticoids for IgG4-related disease: a European retrospective multi-center study of 167 patients Marco Lanzillotta1, Jens Vikse2, Elisabetta Goni3, Jasmin Mahajne1, Veronica Batani1, Lorenzo Dagna1, Emanuel Della-Torre1 | 1Unit of Immunology, Rheumatology, Allergy, and Rare Disease, IRCCS Ospedale san Raffaele Milano, Italy; 2Department of Rheumatology, Stavanger University Hospital, Stavanger, Norway; 3Department of Medicine II, University Hospital, Ludwig Maximilian University Munich, Munich Germany
49 -
PO:35:222 | Distinctive Features of Localized Vasculitis of the Gastrointestinal Tract Compared to Takayasu Arteritis: Insights from a Multicenter Cohort Study Vittorio Dibenedetto1|2|3, Alessandro Tomelleri1|2, Corrado Campochiaro1|2, Elena Baldissera1|2, Luca Moroni1|2, Padoan Roberto4, Marco Matucci-Cerinic1|2|3, Lorenzo Dagna1|2|3 | 1Unit of Immunology, Rheumatology, Allergy and Rare Diseases UNIRAR, IRCCS San Raffaele Hospital Milan, Italy; 2Inflammation, Fibrosis and Ageing Intitiative INFLAGE, IRCCS San Raffaele Hospital Milan, Italy; 3Vita-Salute San Raffaele University, Milan, Italy Milan, Italy; 4University Hospital of Padova, Department of Internal Medicine and Rheumatology Padova, Italy
13 -
PO:08:126 | Use of upadacitinib in real-life: the experience of Calabrian rheumatology Vincenzo Raimondo1, Maurizio Caminiti2, Pietro Gigliotti3, Giuseppe Varcasia4, Massimo L'Andolina5, Domenico Olivo6, Roberta Pellegrini7, Pietro Muto8, Marilena Calabria9, Laura Massaro10, Jessica Maria El Luppino11, Salvatore De Bonis12, Giuseppa Pagano Mariano2, Stefania Sorbara3, Virginia Caira4, Mariateresa Cirillo5, Caterina Bruno9, Clodoveo Ferri11 | 1UOC di Reumatologia, Dipartimento SCIAC, Sapienza Università di Roma; 2Dipartimento di Medicina, Clinica di Reumatologia, Università degli Studi di Udine; 3UOC Medicina Interna e Nefrologia, Dipartimento MeSVA, Università degli Studi di L'Aquila; 4UniCamillus, San Camillo Università Internazionale di Scienze della Salute di Roma, Italy; 5Ambulatorio di Reumatologia, Ospedale di Tropea, Tropea, Italy; 6ASP Crotone, Ambulatorio di Reumatologia, Crotone, Italy; 7Ambulatorio di Reumatologia, Ospedale Annunziata di Cosenza, Cosenza, Italy; 8Ambulatorio di Reumatologia, Ospedale di Paola, Paola, Italy; 9Ambulatorio di Reumatologia, SOC di Medicina Interna, AOU Dulbecco, Catanzaro, Italy; 10Ambulatorio di Reumatologia, Ospedale di Praia a Mare, Praia a Mare, Italy; 11Casa di Cura Madonna dello Scoglio, Reparto di Reumatologia, Cotronei, Italy - Affiliazione 12: Ambulatorio di Reumatologia, ospedale di Acri, Acri, Italy
136 -
PO:24:064 | IPF vs CTD-ILD: Survival and Lung Function from an Italian Real-World Cohort Marco Fornaro1, Donato Lacedonia2, Lorenzo Cavagna3, Paolo Airò4, Marco Sebastiani5, Gianluca Sambataro6, Fabio Cacciapaglia7, Angelica Napoletano1, Cosimo De Pace2, Pasquale Tondo2, Giulia Scioscia2, Eleonora Pedretti4, Maria Grazia Lazzaroni4, Carlo Vancheri8, Andreina Manfredi9, Lorenzo Binchessi3, Rocco Capece3, Michele De Ceglie10, Massimo Giotta11, Florenzo Iannone1 | 1Unit of Rheumatology, Department of Precision and Regenerative Medicine - Area Jonica DiMePRe-J, University of Bari, Bari, Italy; 2Department of Medical and Surgical Sciences, University of Foggia Foggia, Italy; 3Department of Internal Medicine and Therapeutics, University of Pavia, Division of Rheumatology, Fondazione IRCCS, Pavia, Italy; 4Rheumatology and Clinical Immunology Unit, Department of Clinical and Experimental Sciences, ASST Spedali Civili Brescia, Italy; 5Rheumatology Unit, AUSL Piacenza, Department of Medicine and Surgery, University of Parma, Parma, Italy; 6Department of Medicine and Surgery, University of Enna Kore, Enna, Italy; 7Rheumatology Service, F. Miulli Hospital and Department of Medicine and Surgery, LUM University, Casamassima, Italy; 8Department of Clinical and Experimental Medicine, Regional Referral Center for Rare Lung Diseases, Catania, Italy; 9Rheumatology Unit, IRCCS Santa Maria Nuova Reggio Emilia, University of Modena, Modena, Italy; 10DIM, Interdisciplinary Department of Medicine, Section of Diagnostic Imaging, University of Bari, Bari, Italy; 11Health Prevention Department, Local Health Authority of Brindisi, Brindisi, Italy
27 -
PO:07:099 | Survival on therapy of certolizumab pegol in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: 8-year data from an Italian multicenter register Maria Manara1, Gilberto Cincinelli1|2, Marco Fornaro3, Simone Perniola4, Elisa Gremese5, Chiara Bazzani6, Serena Bugatti7, Francesca Romana Spinelli8, Rosario Foti9, Marco Sebastiani10, Alberto Cauli11, Fabiola Atzeni12, Giovanni Lapadula13, Gianfranco Ferraccioli14, Fabrizio Conti8, Florenzo Iannone3, Roberto Caporali1|2 | 1Department of Rheumatology and Medical Sciences, ASST G. Pini-CTO Milano; 2Department of Clinical Sciences and Community Health, University of Milan; 3Department of Precision and Regenerative Medicine and Ionian Area, University of Bari; 4Clinical Immunology Division, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma; 5Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, Rozzano (MI); 6Unit of Rheumatology and Clinical Immunology, ASST Spedali Civili Brescia; 7Department of Internal Medicine and Therapeutics, Università di Pavia; 8Rheumatology Unit, Dipartimento Scienze Cliniche Internistiche, Anestesiologiche e Cardiovascolari, Sapienza University, Roma; 9Rheumatology Unit, San Marco Hospital, Policlinico University of Catania; 10Rheumatology Unit, AUSL Piacenza, University of Parma; 11UOC di Reumatologia, Dipartimento di Scienze Mediche e Sanità Pubblica, Azienda Ospedaliero-Universitaria di Cagliari; 12Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina; 13Gruppo Italiano di Studio sulla Early Arthritis, GISEA, Bari; 14Department of Medicine, Università Cattolica del Sacro Cuore, Fondazione IRCCS Policlinico Gemelli, Roma, Italy
151 -
PO:26:088 | Rheumatologic immune-related adverse events from immune checkpoint inhibitors: a monocentric retrospective study Giulio Fraticelli1|2, Nicola Farina1|2, Alessandro Tomelleri1|2, Marco Matucci Cerinic1|2, Corrado Campochiaro1|2, Lorenzo Dagna1|2. | 1Unit of Immunology, Rheumatology, Allergy and Rare Diseases UNIRAR, IRCCS San Raffaele Hospital, Milano, Italy; 2Inflammation, Fibrosis and Ageing Initiative INFLAGE, IRCCS San Raffaele Hospital, Milano, Italy.
136 -
PO:04:046 | Achieving Early Clinical Response was Associated with Cumulative Benefits on Disease Impact up to 2 Years in Patients with Active Psoriatic Arthritis Treated with Bimekizumab William Tillett1|2, Joseph F Merola3, Iain B Mcinnes4, Kenneth B Gordon5, Richard B Warren6, Patrick Healy7, Jérémy Lambert8, Heather Edens9, Barbara Ink10, Paola Volpe11, Laure Gossec12 | 1Royal National Hospital of Rheumatic Diseases Bath, United Kingdom; 2Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath Bath, United Kingdom; 3Department of Dermatology and Department of Medicine, Division of Rheumatology, Utah Southwestern Medical Center Dallas, USA; 4College of Medical Veterinary and Life Sciences, University of Glasgow Glasgow, United Kingdom; 5Department of Dermatology, Medical College of Wisconsin Milwaukee, USA; 6Northern Care Alliance, NHS Foundation Trust and Manchester Academic Health Science Centre, University of Manchester Manchester, United Kingdom; 7UCB Morrisville, USA; 8UCB Colombes, France; 9UCB Smyrna, USA; 10UCB Slough, United Kingdom; 11UOC Reumatologia, P.O. Spirito Santo Pescara, Italy; 12Sorbonne Universite and Pitie-Salpetriere Hospital Paris, France
27 -
CO:09:3 | Effectiveness and safety of nintedanib in autoimmune systemic diseases: real life data from an Italian multicentre study (Island group) of the Italian Society of Rheumatology Corrado Campochiaro1, Paola Conigliaro2, Gianluca Sambataro3, Marco Matucci-Cerinic1, Marco Sebastiani4, Gianluca Bajocchi5, Angelo Fassio6, Elena Treppo7, Elisabetta Zanatta8, Elena Bartolini9, Francesco Ferro10, Chiara Bazzini11, Nicoletta Del Papa12, Gemma Lepri13, Andrea Lo Monaco14, Marta Favero15, Annamaria Iuliano16, Francesca Li Gobbi17, Maria Sole Chimenti2, Giuseppe Muscato18, Giacomo De Luca1, Francesca Cozzini4, Lucia Dardani5, Francesco Pollastri6, Alessandro Gattron7, Beatrice Moccaldi8, Caterina Antonini9, Gaetano La Rocca10, Ilaria Cavazzana11, Andreina Manfredi5|19. | 1IRCCS San Raffaele Hospital, Vita-Salute San Raffaele, Milano; 2U.O.C. Reumatologia Dipartimento di Medicina dei Sistemi Università di Roma-Tor Vergata, Roma; 3Università Kore, Enna; 4University of Parma, Azienda Ospedaliera di Piacenza; 5UOC Reumatologia, AUSL IRCCS Reggio Emilia; 6UOC Reumatologia Università degli Studi di Verona; 7Dipartimento di Medicina, Clinica di Reumatologia, Università degli Studi di Udine; 8UOC Reumatologia, Dipartimento di Medicina DIMED, Azienda Ospedale Università di Padova; 9SC Interaziendale di Reumatologia, Dipartimento di Medicina e Chirurgia, Università di Perugia, Azienda Integrata Università; 10Dipartimento di Medicina Clinica e Sperimentale UO Reumatologia-Universitaria AOU Pisa; 11U.O. Reumatologia e Immunologia Clinica ASST Spedali Civili di Brescia; 12Clinica Reumatologica, Milano; 13S.O.D. di Reumatologia AOU Careggi, Firenze; 14UOC Reumatologia Azienda Ospedaliero-Universitaria Sant'Anna, Ferrara; 15Internal Medicine I, Department of Medicine, Ca' Foncello Hospital, AULSS2 Marca Trevigiana, Treviso; 16UOC Reumatologia, AO San Camillo Forlanini, Roma; 17Rheumatology Unit, S.Giovanni di Dio Hospital, Firenze; 18Department of Clinical and Experimental Medicine, Regional Referral Center for Rare Lung Disease, Policlinico, Catania; 19Università degli Studi di Modena e Reggio Emilia, Italy
124 -
PO:32:182 | Disease characteristics of anti-centromere positive systemic sclerosis patients and risk factors for organ involvement: data from the EUSTAR cohort Corrado Campochiaro1, Jelena Colic2, Del Papa Nicoletta3, Oliver Distler4, Serena Guiducci5, Florenzo Iannone6, David Launay7, Yair Levy8, Britta Maurer9, Arsene Mekinian10, Predrag Ostojic2, Gabriela Riemekasten11, Petros Sfikakis12, Bojana Stamenkov13, Ulrich Walker14, Marie Elise Truchetet15, Madelon Vonk16, Francesco Del Galdo17, Giacomo De Luca1, Lorenzo Dagna1, Marco Matucci Cerinic1, Yannick Allanore18 | 1IRCCS San Raffaele Hospital; Vita Salute San Raffaele University Milan, Italy; 2University of Belgrade Belgrade, Serbia; 3UOC Reumatologia Clinica, ASST G. Pini CTO Milan, Italy; 4University Hospital Zurich Zurich, Switzerland; 5Department of Rheumatology, University of Florence Florence, Italy; 6Rheumatology Unit Bari, Italy; 7CHU Lille Lille, France; 8Department of Medicine Kfar Saba, Israel; 9Department for BioMedical Research, University of Bern Bern, Switzerland; 10Service de medecine interne Paris, France; 11Department of Rheumatology University of Lubeck Lubeck Germany; 12National and Kapodistrian University of Athens Athens, Greece; 13University School of Medicine, Nis Nis, Serbia; 14University Hospital Basel, Basel Basel, Switzerland; 15Bordeaux Hospital and University Bordeaux, France; 16Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; 17Leeds Institute of Rheumatic and Muskuloskeletal Medicine Leeds, United Kingdom; 18Cochin Hospital Paris, France
16 -
CO:01:1 | Efficacy and safety of rituximab across the four phenotypes of IgG4-related disease: a European multi-center cohort study of 115 patients Marco Lanzillotta1, Jens Vikse2, Elisabetta Goni3, Veronica Batani1, Jasmin Mahajne1, Lorenzo Dagna1, Emanuel Della Torre1. | 1Unit of Immunology, Rheumatology, Allergy, and Rare Disease, IRCCS Ospedale San Raffaele, Milano, Italy; 2Department of Rheumatology, Stavanger University Hospital, Norway; 3Department of Medicine II, University Hospital, Ludwig Maximilian University, Munich, Germany
279 -
PO:14:197 | Safety of biologic and conventional immunosuppressants in an Italian cohort of patients with systemic lupus erythematosus: a longitudinal analysis from the Lupus Italian Registry pharmacoepidemiologic study promoted by the Italian Society of Rheumatology Davide Rozza1, Carlo Alberto Scirè1|2, Paola Conigliaro3, Giacomo Emmi4, Laura Coladonato6, Salvatore Scarpato7, Luca Iaccarino8, Serena Guiducci9, Giulia Pazzola10, Francesca Romana Spinelli11, Micol Frassi12, Ilaria Cavazzana12, Chiara Scirocco13, Valeria Orefice13, Immacolata Prevete13, Alessandra Bortoluzzi14, Marcello Govoni14, Elena Bartoloni15, Luca Moroni16, Giuseppe Alvise Ramirez16, Valentina Canti16, Giorgio Pettiti17, Maria Chiara Ditto18, Enrico Fusaro18, Marta Mosca19, Lorenzo Cavagna20, Fabrizio Conti11, Andrea Doria8, Gian Domenico Sebastiani13, Sperimentatori Gruppo Lire5 | 1Centro Studi della Società Italiana di Reumatologia, Milano; 2Dipartimento di Medicina e Chirurgia, Università degli Studi di Milano-Bicocca, Monza; 3Università di Roma Tor Vergata; 4Dipartimento di Scienze Mediche, Chirurgiche e della Salute, Università di Trieste; 5https://redcap.reumatologia.it/surveys/?s=LWL7WJM4KHDR97CC; 6Dip di Medicina di Precisione e Rigenerativa e area Jonica, Bari; 7Azienda Sanitaria Locale ASL Salerno; 8Università degli Studi di Padova; 9SOD Reumatologia, Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze; 10Arcispedale Santa Maria Nuova Reggio Emilia; 11Università degli Studi di Roma La Sapienza; 12Spedali Civili di Brescia; 13Azienda Ospedaliera San Camillo Forlanini, Roma; 14Azienda Ospedaliera Universitaria Sant'Anna, Ferrara; 15SC Reumatologia, Dipartimento di Medicina e Chirurgia, Università di Perugia; 16IRCCS Ospedale San Raffaele, Milano; 17Azienda Ospedaliera S. Croce e Carle, Cuneo; 18AOU Citta' della Salute e della Scienza di Torino; 19AOU Santa Chiara, Pisa; 20Università di Pavia, Italy
144 -
PO:35:233 | Tocilizumab is associated with improved relapse-free survival in polymyalgia rheumatica: a multicentre retrospective study Milena Bond1, Giovanni Adami2, Marianna Tamussin3, Mario Frasca4, Sara Zandonella Callegher1, Marcello Govoni3, Maurizio Rossini2, Lorenzo Dagna4, Marco Matucci Cerinic4, Christian Dejaco1, Alessandro Tomelleri4 | 1Department of Rheumatology, Brunico Hospital ASAA-SABES, Teaching Hospital of the Paracelsius Medical University Bunico, Italy; 2Rheumatology Unit, University of Verona, Policlinico Borgo Roma Verona, Italy; 3Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S. Anna Ferrara, Italy; 4Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital Milano, Italy
18 -
PO:11:171 | Subcutaneous tocilizumab use in a young-onset mixed connective tissue disease patient with multiple treatment failures Rhaysa Araujo Mousinho1, Elide Lupi2, Massimiliano Limonta2 | 1Clinica di Reumatologia, Dipartimento di Medicina and 2Istituto di Anatomia Patologica, Dipartimento di Medicina di Laboratorio, Osp. S. M. della Misericordia, Università di Udine, Italy
144 -
PO:24:059 | Sjögren's disease-associated Fibromyalgia: pitfalls in disease assessment using ESSDAI and ESSPRI Lucia Cristiana Colaprico1, Stefano Stano1, Daniele Domanico1, Maria Iacovantuono2, Eduardo Urgesi3, Fabio Cacciapaglia1|4, Maria Giannotta1, Paola Conigliaro2, Vincenzo Venerito1, Maria Sole Chimenti2, Giuseppe Lopalco1, Florenzo Iannone1 | 1Rheumatology Unit - Department of Precision and Regenerative Medicine, Jonian Area DiPReMeJ, University of Bari, Bari, Italy; 2University of Rome Tor Vergata, Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, Roma, Italy; 3University Cardiologic Unit - Interdisciplinary Department of Medicine - Policlinico University Hospital, University Bari, Italy; 4Rheumatology Service, Internal Medicine Unit F. Miulli General Hospital, Department of Medicine and Surgery, LUM Casamassima, Italy
26 -
PO:24:060 | Evaluation of a Large Language Model Performance in Rating Cutaneous Manifestations of Dermatomyositis: A Comparison with Expert Assessors Gianmarco Roselli1, Marco Fornaro1, Swapnasha Panigrahi2, Sara Sabbagh3, Florenzo Iannone1, Vincenzo Venerito1, Latika Gupta4 | 1Università degli Studi di Bari, Unità di Reumatologia, DiMePRe-J Bari, Italy; 2University of Birmingham Birmingham, United Kingdom; 3Medical College of Wisconsin, Unit of Rheumatology, Department of Paediatrics Milwaukee, USA; 4University of Manchester, Manchester Academic Health Centre, Division of muscoloskeletal and deramatological sciences Manchester, United Kingdom
15
